HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.